SOUTH SAN FRANCISCO, Calif., May 19 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D.,
chairman and chief executive officer of Cell Genesys, will present a company
update at the Fourth Annual Needham Biotechnology Conference in New York, NY
that will be broadcast live over the internet on Wednesday, May 25, 2005 at
2:30 PM EST.
The webcast will be available on the Investor Relations section of the
Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the
live webcast, it will be archived on the site for at least two weeks following
the presentation. To access the replay, go to the Investor Relations section
of the site.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Clinical trials of GVAX(R) cancer vaccines include
an ongoing Phase 3 trial of GVAX(R) vaccine for prostate cancer as well as
trials of GVAX(R) vaccines for leukemia, pancreatic cancer, lung cancer and
myeloma. Clinical programs of oncolytic virus therapies currently include
CG7870 for prostate cancer and CG0070 for bladder cancer. Cell Genesys
continues to hold equity interests in its two former subsidiaries -- Abgenix,
Inc., an antibody products company and Ceregene, Inc., which is developing
gene therapies for neurodegenerative disorders. Cell Genesys is headquartered
in South San Francisco, CA and has manufacturing operations in San Diego, CA,
Hayward, CA and Memphis, TN. For additional information, please visit the
company's website at http://www.cellgenesys.com.
Statements made herein about Cell Genesys and its subsidiaries, other than
statements of historical fact, including statements about the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of research and
development programs, the success of clinical trials, the regulatory approval
process, competitive technologies and products, patents and additional
financings. For information about these and other risks that may affect Cell
Genesys, please see the company's Annual Report on Form 10-K for the year
ended December 31, 2004 dated March 14, 2005, as well as Cell Genesys' reports
on Forms 10-Q and 8-K and other reports filed with the Securities and Exchange
Commission.
Contact: Ina Cu
Investor Relations
Cell Genesys, Inc.
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations of Cell Genesys,
Inc., +1-650-266-3200
|
